Tumor neoantigen vaccine system specifically marking heterologous protein, and use thereof

Through the tumor neoantigen vaccine system that specifically labels heterologous proteins, the method of binding of heterologous protein mRNA vaccine and recombinant oncolytic viruses has been used to solve the problem of poor response to tumor neoantigen vaccine treatment, achieving efficient anti-tumor immune effects and significant improvement in the treatment response rate.

WO2025081515A1 Publication Date: 2025-04-24CHINA PHARM UNIV
2 Cites 1 Cited by

Patent Information

Application Number
PCT/CN2023/125912
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2023-10-17
Filing Date
2023-10-23
Publication Date
2025-04-24

AI Technical Summary

Technical Problem

The response rate of existing tumor neoantigen vaccines is poor, mainly due to the inhibition of treatment response by low immunogenicity, differential expression and time limit (TIME).

Method used

A tumor neoantigens vaccine system is used that specifically labels heterologous proteins. This system consists of heterologous protein mRNA vaccine and recombinant oncolytic viruses. Memory T cells are induced through heterologous protein mRNA vaccines, and a strong immunogenic neoantigens are labeled in tumor cells using recombinant oncolytic viruses.

Benefits of technology

The treatment response rate of tumor neoantigen vaccine is improved, and the immune response is further activated by activating systemic antitumor immune effects, killing tumor cells quickly and efficiently and releasing tumor autoantigens.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The present invention provides a tumor neoantigen vaccine system specifically marking a heterologous protein, and a use thereof. The vaccine system is composed of a heterologous protein mRNA vaccine and a recombinant oncolytic virus; the heterologous protein mRNA vaccine is used to induce an organism to generate heterologous protein-specific memory T cells, and the recombinant oncolytic virus is used to promote a tumor to express microorganism-derived tumor neoantigens. When pre-immunized memory T cells detect these marked specific neoantigens, the tumor expressing the neoantigens is quickly activated and killed, the release of tumor autoantigens is promoted, dendritic cells phagocytize antigens to further initiate an anti-tumor response, and a systemic anti-tumor immune effect is activated by means of antigenic epitope spreading.
Need to check novelty before this filing date? Find Prior Art